PEG门冬酰胺酶治疗急性淋巴细胞白血病患者产生抗PEG和琥珀酸连接臂抗体
结果发现所有患者均检出抗PEG抗体(IgG 100%;IgM 67%),诱导期抗连接臂抗体为主,结论提示抗PEG和抗连接臂抗体在诱导期免疫反应中起主要作用,换用天然大肠杆菌门冬酰胺酶可作为充分治疗的选项。
要点
- 所有对PEG门冬酰胺酶超敏患者均检出抗PEG抗体(IgG 100%)。
- 诱导期抗琥珀酸连接臂抗体IgG 50%、IgM 42%。
- 诱导期抗门冬酰胺酶抗体仅11%,换用天然大肠杆菌门冬酰胺酶可考虑。
核心结论
- 抗PEG和抗琥珀酸连接臂抗体在诱导期对PEG门冬酰胺酶的免疫反应中起主要作用。
- 换用天然大肠杆菌门冬酰胺酶可为充分门冬酰胺酶治疗的选择。
研究设计与样本
- 其中12例超敏反应发生于诱导期首次PEG门冬酰胺酶剂量,6例发生于中断数月后的强化期。
- 采用ELISA检测抗体,包被琥珀酰亚胺琥珀酸连接臂偶联BSA、PEG非格司亭和大肠杆菌门冬酰胺酶。
主要发现
- 所有患者检出抗PEG抗体(IgG 100%;IgM 67%),其中39%仅检出抗PEG抗体。
- 既往未接受PEG化治疗的患者也检出预存抗PEG抗体(IgG 58%;IgM 21%)。
- 抗琥珀酸连接臂抗体主要在诱导期检出(IgG 50%;IgM 42%)。
- 抗门冬酰胺酶抗体在诱导期仅11%检出,强化期达94%。
临床怎么用
- 对PEG门冬酰胺酶超敏患者应检测抗PEG及抗连接臂抗体。
- 诱导期超敏且抗门冬酰胺酶抗体阴性者可考虑换用天然大肠杆菌门冬酰胺酶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polyethylene glycol (PEG) conjugated asparaginase (PEGasparaginase) is essential for treatment of paediatric acute lymphoblastic leukaemia. We developed an assay identifying antibodies against the PEG-moiety, the linker and the drug itself in patients experiencing hypersensitivity reactions to PEGasparaginase. Eighteen patients treated according to the DCOG ALL-11 protocol, with a neutralizing hypersensitivity reaction to PEGasparaginase to the first PEGasparaginase doses in induction (12 patients) or during intensification after interruption of several months (6 patients) were included. ELISA was used to measure antibodies, coating with the succinimidyl succinate linker conjugated to BSA, PEGfilgrastim and Escherichia coli asparaginase, and using hydrolysed PEGasparaginase and mPEG5,000 for competition. Anti-PEG antibodies were detected in all patients (IgG 100%; IgM 67%) of whom 39% had anti-PEG antibodies exclusively. Pre-existing anti-PEG antibodies were also detected in patients who not previously received a PEGylated therapeutic (58% IgG; 21% IgM). Antibodies against the SS-linker were predominantly detected during induction (50% IgG; 42% IgM). Anti-asparaginase antibodies were detected in only 11% during induction but 94% during intensification. In conclusion, anti-PEG and anti-SS-linker antibodies predominantly play a role in the immunogenic response to PEGasparaginase during induction. Thus, switching to native E. coli asparaginase would be an option for adequate asparaginase treatment.
引用
- Kloos R, van der Sluis IM, Mastrobattista E, et al. Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker. Br J Haematol. 2019. PMID: 31883112. doi:10.1111/bjh.16254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。